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Abstract
Background: Nucleic acid amplification tests are sensitive for identifying Mycobacterium tuberculosis in populations with
positive sputum smears for acid-fast bacilli, but less sensitive in sputum-smear-negative populations. Few studies have
evaluated the clinical impact of these tests in low-income countries with high burdens of TB and HIV.
Methods: We prospectively enrolled 211 consecutive adults with cough $2 weeks and negative sputum smears at Mulago
Hospital in Kampala, Uganda. We tested a single early-morning sputum specimen for Mycobacterium tuberculosis DNA
using two nucleic acid amplification tests: a novel in-house polymerase chain reaction targeting the mycobacterial secA1
gene, and the commercial AmplifiedH Mycobacterium tuberculosis Direct (MTD) test (Gen-Probe Inc, San Diego, CA). We
calculated the diagnostic accuracy of these index tests in reference to a primary microbiologic gold standard (positive
mycobacterial culture of sputum or bronchoalveolar lavage fluid), and measured their likely clinical impact on additional
tuberculosis cases detected among those not prescribed initial TB treatment.
Results: Of 211 patients enrolled, 170 (81%) were HIV-seropositive, with median CD4+ T-cell count 78 cells/mL (interquartile
range 29-203). Among HIV-seropositive patients, 94 (55%) reported taking co-trimoxazole prophylaxis and 29 (17%)
reported taking antiretroviral therapy. Seventy-five patients (36%) had culture-confirmed TB. Sensitivity of MTD was 39%
(95% CI 28–51) and that of secA1 was 24% (95% CI 15–35). Both tests had specificities of 95% (95% CI 90–98). The MTD test
correctly identified 18 (24%) TB patients not treated at discharge and led to a 72% relative increase in the smear-negative
case detection rate.
Conclusions: The secA1 and MTD nucleic acid amplification tests had moderate sensitivity and high specificity for TB in a
predominantly HIV-seropositive population with negative sputum smears. Although newer, more sensitive nucleic acid
assays may enhance detection of Mycobacterium tuberculosis in sputum, even currently available tests can provide
substantial clinical impact in smear-negative populations.
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Introduction
In 2009, 43% of the 4.6 million new pulmonary tuberculosis
cases reported to the World Health Organization were diagnosed
without microbiologic confirmation [1]. The failure to confirm a
diagnosis with microbiologic testing can result in inappropriate
management due to misdiagnosis and failure to initiate appropri-
ate therapy early in the disease process. These disadvantages are
especially relevant in low-income countries where supplementary
imaging and laboratory data are usually not available to support
an empiric diagnosis, and where late presentation for care is more
common. A timely and accurate diagnosis of TB must be made if
treatment is to be successful and person-to-person transmission
reduced. Given the logistical challenges of making reliable sputum
smear microscopy and culture facilities widely available, a simple,
highly accurate, and rapid diagnostic test could have a dramatic
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impact on worldwide TB transmission, morbidity, and mortality
[2].
Nucleic-acid amplification tests (NAATs) targeting Mycobacte-
rium tuberculosis (MTB) have enormous potential to improve TB
case detection, with commercial NAATs, such as the GenProbe
AmplifiedH Mycobacterium Tuberculosis Direct (MTD) Test
(Gen-Probe Inc, San Diego, CA), reported to have nearly perfect
sensitivity in sputum smear-positive patients and a sensitivity of
61–76% in smear-negative patients [3,4,5,6]. We have previously
shown in a small study that a novel NAAT targeting a conserved
region of the mycobacterial-genus secA1 gene and capable of
identifying all clinically significant species of mycobacteria
including M. tuberculosis, has a sensitivity of 100% and a
specificity of 90% in sputum smear-negative TB suspects in
Uganda, most of whom were HIV-seropositive [7]. In the current
study, we evaluated the diagnostic accuracy, incremental value,
and potential clinical impact of the secA1 and MTD NAATs in a
population at high risk for both HIV and TB.
Materials and Methods
Ethics Statement
The Makerere University Faculty of Medicine Research Ethics
Committee, the Mulago Hospital Institutional Review Board, the
Uganda National Council for Science and Technology, and the
University of California San Francisco Committee on Human
Research approved the protocol. Some of these patients have been
previously included in published studies [8,9,10,11,12,13,14,15].
Participants
Between September 2007 and May 2008, we prospectively
enrolled consecutive inpatients $18 years of age who were
admitted to Mulago Hospital in Kampala, Uganda, with cough
$2 weeks duration into a protocol designed to provide a detailed
evaluation (including HIV testing, chest radiography, sputum
examination, and bronchoscopy) to identify the etiology of each
patient’s pulmonary symptoms. Patients with a prior history of TB
within two years and those receiving treatment for active TB at the
time of hospitalization were excluded. For the current analysis, we
included only patients without a positive sputum smear examina-
tion by the Ziehl-Neelsen technique, which was the standard
method for smear examination at the time of the study.
Patient Data and Specimen Collection
After obtaining written informed consent from participants,
study medical officers recorded demographic and clinical
information following a standardized interview, physical exam,
and frontal chest radiography. A laboratory technician gave
standardized instructions on proper sputum submission [16], after
which each patient provided two sputum samples (one spot sample
on day one and one early-morning sample on day two) for
microscopic examination and culture. The technician recorded the
volume and quality of sputum according to technical guidelines
[17]. Study medical officers referred HIV-seropositive patients
with negative acid-fast bacilli (AFB) smears for bronchoscopy with
bronchoalveolar lavage (BAL). Chest physicians performed
bronchoscopy according to a standardized protocol that included
airway inspection for Kaposi’s sarcoma lesions and collection of
BAL fluid for microbiologic examination including mycobacterial
smear and culture. Full details of bronchoscopy and examination
of the clinical specimens have been previously described [11].
At discharge, we asked patients to return in two months for a
follow-up clinical evaluation and repeat sputum examination if still
symptomatic. After participants had completed all study proce-
dures and the two-month follow-up visit, at least two pulmonary
physicians reviewed all available clinical and microbiologic data,
and assigned final diagnoses according to explicit clinical
definitions as previously described [11].
Specimen Testing by Smear Microscopy and
Mycobacterial Culture
At enrollment, National TB Reference Lab (NTRL) staff
examined sputum specimens by direct Ziehl-Neelsen light
microscopy and NALC-NaOH concentrated auramine-O fluores-
cence microscopy using a mercury-vapor lamp, and recorded
results semi-quantitatively. In addition, they inoculated Low-
enstein-Jensen solid-culture media with concentrated sediment
from every sputum and BAL fluid sample collected. Technicians
considered cultures positive for MTB when mycobacterial growth
of $1 colony-forming unit (CFU) was observed within eight weeks
of incubation. Positive cultures were confirmed by Ziehl-Neelsen
staining, and the amount of growth recorded semi-quantitatively
[18].
Specimen Nucleic Acid Amplification Testing
One-third of the concentrated early-morning sputum pellet
remaining after preparation of the microscopy slides and culture
slants was frozen and shipped to the National Institutes of Health
(NIH) Clinical Center, Bethesda, MD. There it was thawed and
divided into two aliquots, which were then randomly labeled and
assayed independently in a blinded manner. One aliquot was
tested with an in-house polymerase chain reaction (PCR) assay
targeting the MTB gene coding for the protein SecA1 as
previously described [7,19]. Briefly, specimens were processed
for DNA extraction by ultrasonication for 15 minutes with
zirconia/silica beads (BioSpec Products, Bartlesville, OK) in a
Tris-HCl buffer containing n-acetyl-cysteine and sodium-dodecyl-
sulfate, and then placed in NucliSens lysis buffer (Biomerieux,
Boxtel, The Netherlands). DNA was purified using a QIAamp
DNA Blood Mini Kit (Qiagen, Germantown, MD). Real-time
PCR was performed on a LightCycler (Roche, Basel, Switzerland)
using primers targeting a 490-nucleotide region of the secA1 gene
[19]. PCR amplification products were detected using fluores-
cence-resonance energy-transfer (FRET) probes specific for M.
tuberculosis complex. Two PCR assays for each sample were
performed in separate capillary tubes, one of which was spiked
with a plasmid containing an internal-control sequence to allow
detection of PCR inhibition. Samples that showed inhibition were
repeated using 1:3 to 1:100 dilutions as necessary to overcome
inhibition. For each PCR run, a negative control (without
template DNA) was run to detect contamination. Additional
procedures to avoid DNA carry-over were utilized as previously
described [7].
The second aliquot was assayed per the manufacturer’s protocol
using the Gen-Probe Amplified MTD test, which makes multiple
copies of a specific MTB 16S-ribosomal RNA sequence for
detection by hybridization with a chemiluminescent probe. If a
specimen had a chemiluminescence of ,30,000 relative light
units, it was considered negative, while a positive sample was
required to be $500,000 units. Specimens between 30,000 units
and 499,999 units were re-run, and if the repeat sample was again
$30,000 units, it was considered positive, as per the manufactur-
er’s protocol. For both secA1 PCR and the MTD assay, a positive
control (M. tuberculosis) and a negative control (M. gordonae)
were included with each run.
Laboratory investigators were blinded to all clinical and culture
data. NAAT results were independently classified as positive or
negative for MTB by two investigators (JAK, CH), with a
NAAT for Smear-Negative TB Diagnosis in Uganda
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consensus reading reached after joint review of discrepant results.
The secA1 and MTD data were unblinded only after a final
assignment had been made for all samples.
Statistical Analysis
We used STATA 11.0 (Stata Corporation, College Station, TX)
for statistical analyses and defined a finding as significant if the
probability of a two-tailed, type-I error (p-value) was ,0.05. We
calculated sensitivity, specificity, positive predictive value, and
negative predictive value of each of the sputum NAATs in
reference to two separate gold standards. For the primary analysis,
we defined TB as present if a patient had $1 positive sputum or
BAL mycobacterial culture. As a secondary analysis, we defined
TB as present if cultures were positive or if a patient was clinically
diagnosed with culture-negative TB at the 2-month follow-up visit.
We planned in advance to compare diagnostic performance by
HIV status using a two-sample test of proportions for unpaired
samples. Assuming a TB prevalence of 30% and a sample size of
210 patients, we estimated that we would have 89% power to
detect a 15% or larger increase in sensitivity for the secA1 NAAT
compared to the MTD NAAT (previously reported as 76% in
smear-negative patients), and 84% power to show that the
specificity of the secA1 assay was within 5% of the previously
reported value for the MTD assay of 97% [5]. Finally, we
estimated the incremental value (additional sensitivity) of the two
NAATs as add-on tests after smear microscopy [20] and measured
the potential clinical impact on time-to-treatment initiation if a
NAAT result were used to prescribe TB treatment, compared to
clinical judgment alone [21].
Results
Participants
Four hundred seventy consecutive adult patients with cough $2
weeks were enrolled in the overall study. One hundred seventy-six
were sputum AFB smear-positive by Ziehl-Neelsen staining, which
had a sensitivity of 66%; 26 had only one sputum collected; eight
patients had missing sputum samples; and seven patients were
missing AFB results. Of the remaining 253 patients, 42 were
excluded because culture results or final diagnoses were unknown,
leaving 211 patients for this analysis (Figure 1).
Patients had a median age of 35 years (inter-quartile range
(IQR) 28–42; Table 1). Slightly more patients were female (114,
54%) than male, and the majority had received antibiotics prior to
hospital admission (139, 66%). Most patients were HIV-seropos-
itive (170, 81%), with a median CD4+ T-cell count of 78 cells/mL
(IQR 29–203 cells/mL); 94 (55%) of the HIV-seropositive patients
were taking PCP prophylaxis, and 29 (17%) were taking
antiretroviral therapy. Patients with HIV tended to be younger
(median age 34 years, IQR 28–39) than patients without HIV
(median age 48 years, IQR 34–62; p,0.001), and more often
female (57% vs. 41%; p= 0.072). Fifty-two of the 211 patients with
negative sputum exams by conventional light microscopy had
positive sputum smear examinations using concentrated fluores-
cence microscopy, but only 34 of these 52 patients (65%) had a
confirmed TB diagnosis by mycobacterial culture or clinical
follow-up. One hundred nine patients (52%) underwent bron-
choscopy. No adverse events arose as a result of sputum collection
or bronchoscopy. The clinical impacts of fluorescence microscopy
Figure 1. Patients enrolled, eligible, and analyzed.
doi:10.1371/journal.pone.0016321.g001
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and of bronchoscopy in this population have been previously
described [9,13].
Seventy-five of the 211 patients (36%) had culture positive TB.
An additional 17 patients who had negative mycobacterial cultures
met clinical criteria for TB, while for 44 patients, an in-person
clinical assessment could not be made because no follow-up
evaluation occurred at two months. Thus, a total of 92 (55%) out
of 167 patients had culture-confirmed or clinically confirmed TB.
Among 193 patients with known vital status at two months, 46
(24%) had died, including 41 (26%) HIV-positive and 5 (14%)
HIV-negative patients (mortality difference 12%, 95% CI -1 to
+25, p = 0.13).
Results of Sputum NAATs
Using mycobacterial culture results as the gold standard, the
sensitivity of MTD for diagnosing TB was 39% (95% Confidence
Interval (CI) 28–51), which was 15% higher (95% CI 2–27, p=0.019)
than that of secA1, which had a sensitivity of 24% (95% CI 15–35;
Table 2). The specificities of MTD (95%, 95% CI 90–98) and secA1
(95%, 95% CI 90–98) were the same (specificity difference 0%, 95%
Table 1. Demographic and clinical characteristics of the 211 study participants.
Characteristics
N (%)*
All patients
(n =211)
HIV-seropositive
(n =170)
HIV-seronegative
(n =41)
Median age, years (IQR) 35 (28–42) 34 (28–39) 48 (34–62)
Women 114 (54) 97 (57) 17 (41)
Taking antibiotics prior to admission 139 (66) 115 (68) 24 (59)
Median CD4+ T-cell count, cells/mL (IQR) - - 139 (29–203) - -
Taking co-trimoxazole prophylaxis on admission - - 94 (55) - -
Taking antiretroviral therapy on admission - - 29 (17) - -
Culture-confirmed TB 75 (36) 67 (39) 8 (20)
Clinically confirmed or culture-confirmed TB 92 (55){ 81 (61){{ 11 (32){{{
Two-month mortality 46 (24)1 41 (26)11 5 (14)111
Abbreviations: IQR, inter-quartile range; N, number; TB, tuberculosis.
Legend: *Characteristics presented as number and column percentage unless otherwise indicated. Missing or indeterminate results reduced the number at risk in the
superscripted subsets as follows: {N= 167; {{N= 133; {{{N= 34; 1N=193; 11N= 157; 111N=36.
doi:10.1371/journal.pone.0016321.t001
Table 2. Diagnostic performance of nucleic acid amplification tests for TB, compared to both the primary and secondary reference
standards.
Index Test
Results
Reference Positive
(N)
Reference Negative
(N)
Percent Sensitivity
(95% CI)
Percent Specificity
(95% CI)
Mycobacterial culture reference standard 75 136
MTD
Positive 29 7 39% (28–51) 95% (90–98)
Negative 46 129
Indeterminate - -
secA1 24% (15–35) 95% (90–98)
Positive 18 7
Negative 57 128
Indeterminate - 1
Clinical TB reference standard 92 75
MTD 32% (22–42) 97% (91–100)
Positive 29 2
Negative 63 73
Indeterminate - -
secA1 20% (12–29) 99% (93–100)
Positive 18 1
Negative 74 74
Indeterminate - -
Abbreviations: CI, confidence interval; IQR, inter-quartile range; MTD, Gen-Probe AmplifiedH Mycobacterium Tuberculosis Direct test; secA1, secretory gene A1 target
test; TB, tuberculosis.
doi:10.1371/journal.pone.0016321.t002
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CI24.3 to +4.3, p=1.0). The positive predictive value for MTD was
81% (95%CI 64–92), and the negative predictive value was 74% (95%
CI 67–80). The secA1 had a positive predictive value of 72% (95% CI
51–88), and a negative predictive value of 69% (95% CI 62–76). One
patient had an indeterminate secA1 result secondary to PCR inhibition
that could not be overcome by dilution.
When clinically-defined TB was used as the reference standard,
both tests had slightly lower sensitivities but higher specificities.
MTD had a sensitivity of 32% (95% CI 22–42) and secA1 a
sensitivity of 20% (95% CI 12–29), with a sensitivity difference of
12% (95% CI 2–22, p = 0.019). Again, the specificity of MTD
(97%, 95% CI 91–100) and secA1 (99%, 95% CI 93–100) were
similar (specificity difference 1.3%, 95% CI 22.6 to +5.3, p = 1.0).
The positive predictive value of MTD was 94% (95% CI 79-99),
and the negative predictive value was 54% (95% CI 45–62). The
secA1 had a positive predictive value of 95% (95% CI 74–100) and
a negative predictive value of 50% (95% CI 42–58).
Both the secA1 and the MTD tests had a higher sensitivity in
HIV–seropositive patients than HIV-seronegative patients, using
culture as the reference standard, although the precision of the
estimates among HIV-seronegatives was limited by the small
number of patients (n = 41, Table 3). MTD had a sensitivity of
42% (95% CI 30–55) among HIV-seropositive patients and a
sensitivity of 13% (95% CI 0–53) among HIV-seronegative
patients (difference in sensitivity, 29%, 95% CI 27 to +65,
p = 0.14). The secA1 had a sensitivity of 25% (95% CI 16–38)
among HIV-seropositive patients, and 13% (95% CI 0–53) among
HIV-seronegative patients (difference in sensitivity, 13%, 95% CI
219 to +44, p = 0.67). There were no major differences in sputum
quality, volume, smear-grade, or culture-grade between patients
with and without HIV (data not shown).
Potential Clinical Impact of Nucleic Acid Amplification
Testing
At hospital discharge, only 25 (33%) of 75 AFB smear-negative
patients ultimately diagnosed with culture-positive TB had been
prescribed TB treatment. Had results of the more sensitive of the
two NAATs, the MTD, been made available to clinicians within
24 hours of sputum collection, 18 additional TB patients could
have been correctly started on TB treatment, while only two
patients with negative mycobacterial cultures would have been
inappropriately started on treatment. Thus, availability of MTD
results would have lead to an absolute increase in sensitivity for TB
of 24%, and a relative increase of 72% in early TB case detection
among the Ziehl-Neelsen AFB-smear-negative population (43 TB
patients if MTD results had been available compared to 25 TB
patients when MTD results were not available). Instead of waiting
for culture results to initiate TB treatment, these patients could
have been started a median of 27 days (range 15–42 days) earlier.
Unfortunately, 10 of these 18 smear-negative, MTD-positive,
culture-positive TB patients died a median of 8.5 days (range 4–13
days) after enrollment, and it is unknown whether earlier initiation
of treatment for these patients would have improved their
outcomes.
NAAT Performance and Impact among Patients Smear-
negative by Fluorescence Microscopy
Among 159 patients with negative fluorescence microscopy
results, the MTD was 29% (95% CI 17–44) sensitive in reference
to mycobacterial culture, while secA1 was only 8% sensitive (95%
CI 2–20). Both NAATs were equally specific in fluorescence
microscopy smear-negative patients (98%, 95% CI 94–100).
Table 3. Diagnostic performance of nucleic acid amplification tests for TB stratified by HIV status, compared to the primary
reference standard only.
Index Test
Results
Reference Positive
(N)
Reference Negative
(N)
Percent Sensitivity
(95% CI)
Percent Specificity
(95% CI)
Mycobacterial culture reference standard 75 136
HIV-seropositive patients 67 103
MTD 42% (30–55) 93% (87–97)
Positive 28 7
Negative 39 96
Indeterminate - -
secA1 25% (16–38) 93% (86–97)
Positive 17 7
Negative 50 95
Indeterminate - 1
HIV-seronegative patients 8 33
MTD 13% (0–53) 100% (89–100)
Positive 1 0
Negative 7 33
Indeterminate - -
secA1 13% (0–53) 100% (89–100)
Positive 1 0
Negative 7 33
Indeterminate - -
Abbreviations: CI, confidence interval; IQR, inter-quartile range; MTD, Gen-Probe AmplifiedH Mycobacterium Tuberculosis Direct test; secA1, secretory gene A1 target
test; TB, tuberculosis.
doi:10.1371/journal.pone.0016321.t003
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Among 48 fluorescence smear-negative, mycobacterial culture-
positive patients, 12 (25%) patients were empirically initiated on
TB treatment. Had MTD results been available to clinicians, an
additional 10 (21%) patients could have been prescribed treatment
(22 TB patients if MTD results had been available compared to 10
TB patients when MTD results were not available), an 83%
relative increase in the proportion of fluorescence microscopy
smear-negative cases initiated on treatment.
Discussion
Adoption of new technologies for TB diagnosis in highly
endemic areas is a challenge because of the start-up and training
costs. Yet, increased use of molecular tests for TB would permit
more expeditious initiation of treatment and other measures to
reduce TB transmission, which could eventually pay large
dividends for global TB control [22,23]. Although studies suggest
that NAATs are cost-effective for TB diagnosis even in low-income
countries [24,25], this technology has been used to only a limited
extent to evaluate smear-negative TB suspects in sub-Saharan
Africa (Table 4). These studies have reported variable sensitivity
depending on HIV prevalence, but have consistently shown that
these assays can identify a substantial proportion of smear-negative
TB patients. Delays in adopting NAATs for TB reflect ongoing
operational and feasibility concerns in low-income settings [26],
but a lack of information about the clinical impact and
incremental value of these tests beyond the standard diagnostic
algorithm of sputum smear microscopy and clinician judgment
may also have contributed to the slow uptake of this technology
[21,27].
In a prospective diagnostic cohort study of patients suspected of
TB in a low-income country with a high prevalence of TB and
HIV, we have shown that NAATs identify many smear-negative
TB patients whom clinicians would otherwise fail to diagnose.
Although the sensitivities of the NAATs evaluated in our study
were modest compared to mycobacterial culture, we found that, if
routinely applied, same day NAAT would have decreased time-to-
treatment initiation in smear-negative TB patients by almost four
weeks. Because smear-negative TB may account for up-to-half of
all TB cases in sub-Saharan Africa [1], our data suggest that
finding a way to put nucleic acid tests into everyday use could
increase TB case detection in the region by 20% or more.
We undertook this study because prior data from a small cohort
of smear-negative patients suggested that the secA1 assay might
have a high sensitivity in smear-negative patients. In the current
study, however, the in-house secA1 PCR assay was less sensitive
than a commercial amplification assay at identifying MTB in AFB-
smear-negative sputum, although both assays were equally
specific. These results are likely explained by the fact that secA1
is a single-copy gene, whereas the MTD test targets rRNA, which
is present in multiple copies per organism. Because the compa-
rative advantage of the secA1 assay actually lies in its ability to
distinguish multiple mycobacterial species [19], it may be better
suited for use in lower TB incidence settings, where non-
tuberculous mycobacterial pathogens are common and speciation
is clinically important.
The sensitivity of the MTD test was also relatively low in our
study and lower than that reported in previous studies in similar
populations [26]. This may reflect the effects of freezing, storage,
thawing and delayed processing on the integrity of nucleic acids
(especially RNA) in the sputum specimens. More importantly and
especially noteworthy for future demonstration studies of NAATs
in sputum smear-negative populations, the lower sensitivity we
observed could be explained by the higher sensitivity of sputum
smear microscopy (33% in the previous study vs. 66% in our study)
and mycobacterial culture (71% in the previous study vs. 94% in
our study) used to define the eligible population [26]. Use of poor-
quality microscopy to select eligible patients, or poor-quality
cultures to define the reference standard are well-known biases in
diagnostic studies [28,29], biases which are best avoided entirely
by also reporting measures of clinical impact. Thus, it is important
that MTD detected a substantial proportion of untreated cases of
smear-negative TB, whether TB was defined clinically or
microbiologically, and whether smear-negativity was defined using
conventional light or concentrated fluorescence microscopy.
There were some limitations to the study. First, NAATs were
performed in a research laboratory far from the clinical site, which
prevented assessment of the accuracy or feasibility of the tests in
the routine operational setting, and may have resulted in a lower
sensitivity for the reasons noted above. Second, for specimens that
required dilution because of PCR inhibition and proved to be
negative after 3-to-100 fold dilution using the secA1 assay,
improved sensitivity may have been seen if we had been able to
eliminate the inhibition and run the assay at higher concentra-
tions. Third, although the sensitivities of the NAATs in this study
were much higher among HIV-seropositive patients than among
HIV-seronegative patients, we had insufficient power to determine
whether these differences were statistically significant. This will be
Table 4. Diagnostic performance of sputum nucleic acid amplification testing for TB diagnosis among smear-negative TB suspects
in sub-Saharan Africa.
Location (Year) Test
HIV
Prevalence
Percent
Sensitivity
(95% CI) Reference
Zambia (2001) IS6110 PCR 75%* 40 (25–57) [26]
Zambia (2001) Gen-Probe A-MTD 75%* 60 (43–75) [26]
South Africa{ (2010) Cepheid GeneXpert MTB/RIF 66%* 73 (65–79) [6]
Uganda (2009) secA1 PCR 46% 100 (63–100) [7]
Kenya (2004) Roche Amplicor MTB 35% 82{ (76–87) [30]
Abbreviations: IS, insertion sequence; PCR, polymerase chain reaction.
Legend: Studies with 30 or more smear-negative patients from sub-Saharan Africa were included.
*Estimated from population-specific HIV prevalence rather than directly measured;
{Also includes specimens from Azerbaijan, India, and Peru;
{Sensitivity based on 3 PCR specimens.
doi:10.1371/journal.pone.0016321.t004
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an important issue for future studies to address. Finally, neither of
the reference standards used in this study included liquid
mycobacterial culture, which might have provided higher, more
accurate estimates of NAAT specificity and positive predictive
value, and lower estimates of sensitivity and negative predictive
value.
In summary, we carried out a prospective diagnostic cohort
study to evaluate the accuracy and potential effectiveness of
nucleic acid amplification testing for TB diagnosis in a hospitalized
population with a high incidence of HIV, and found modest
sensitivity, excellent specificity, and a large potential clinical
impact. Future studies should identify feasible ways to implement
nucleic acid testing and evaluate them with attention not only to
their diagnostic accuracy but also to their clinical and public
health impact.
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